Right now the infusions business and cardiocel povide the bread and butter revenue to make a going concern and hopefully will be a growth engine. Yes, if the vaccines proved successful it would make sense to buy back a controlling stake even at a higher price.
Thats just being pragmatic, and its the management decision making that has got Admedus back on its feet.
Letter of intent to fund Vacs, page-20
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.04 |
Change
-0.110(0.73%) |
Mkt cap ! $292.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $53.31K | 3.509K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 43 | $15.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.18 | 182 | 3 |
View Market Depth
| Last trade - 13.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |